Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Wennogle Lawrence P.
 2. Date of Event Requiring Statement (Month/Day/Year)
08/29/2013		 3. Issuer Name and Ticker or Trading Symbol
Intra-Cellular Therapies, Inc. [NONE]
(Last)
(First)
(Middle)
C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Vice President, Drug Discovery
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NEW YORK, NY 10032		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 100,000
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (1) 12/16/2013 Common Stock 12,500 $ 0.3 D  
Stock Option (right to buy)   (1) 12/19/2014 Common Stock 37,500 $ 0.5 D  
Stock Option (right to buy)   (1) 12/14/2015 Common Stock 12,500 $ 0.6 D  
Stock Option (right to buy)   (1) 12/05/2016 Common Stock 12,500 $ 1.36 D  
Stock Option (right to buy)   (1) 12/12/2017 Common Stock 12,500 $ 1.5 D  
Stock Option (right to buy)   (1) 12/18/2018 Common Stock 10,000 $ 1.5 D  
Stock Option (right to buy)   (1) 06/10/2020 Common Stock 10,000 $ 2.74 D  
Stock Option (right to buy)   (2) 12/21/2020 Common Stock 10,000 $ 2.74 D  
Stock Option (right to buy)   (3) 04/30/2022 Common Stock 5,000 $ 2.84 D  
Stock Option (right to buy)   (4) 05/30/2023 Common Stock 7,500 $ 3.26 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Wennogle Lawrence P.
C/O INTRA-CELLULAR THERAPIES, INC.
3960 BROADWAY
NEW YORK, NY 10032		       Vice President, Drug Discovery  

Signatures

/s/ Lawrence J. Hineline, Attorney-in-fact 09/09/2013
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) All shares underlying this option have vested.
(2) The option vests as to one third of the shares on December 22, 2011, one third of the shares on December 22, 2012 and one third of the shares on December 22, 2013.
(3) The option vests as to one third of the shares on December 20, 2012, one third of the shares on December 20, 2013 and one third of the shares on December 20, 2014.
(4) The option vests as to one third of the shares on December 20, 2013, one third of the shares on December 20, 2014 and one third of the shares on December 20, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.